NeuroOne® CEO Dave Rosa Featured on Fox Business Network’s Varney & Co.
04 Abril 2024 - 10:00AM
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC)
(“NeuroOne” or the “Company”), a medical technology company focused
on improving surgical care options and outcomes for patients
suffering from neurological disorders, announces an appearance by
Chief Executive Officer Dave Rosa on Fox Business Network's Varney
& Co. on Wednesday April 3rd. The segment, which aired live
yesterday, can be viewed online at Fox Business.
In conversation with veteran business journalist
and commentator Stuart Varney, Mr. Rosa discussed NeuroOne’s newest
offering, a combination diagnostic and therapeutic device that
provides EEG recording capabilities as well as nervous tissue
ablation. This combination offers the potential to reduce the
number of hospitalizations and surgical procedures for patients,
lower costs, and improve patient outcomes. NeuroOne recently
announced a milestone achievement with the limited commercial
launch of its OneRF™ Ablation System, the Company's first
therapeutic electrode technology.
Stuart Varney takes over the critical
market-open coverage with Varney & Co. (9-12PM/ET). The
program, which is amongst the highest rated programs in business
news, breaks down the latest in financial news and political
headlines.
About NeuroOne
NeuroOne Medical Technologies Corporation is a
developmental stage company committed to providing minimally
invasive and hi-definition solutions for EEG recording, brain
stimulation and ablation solutions for patients suffering from
epilepsy, Parkinson's disease, dystonia, essential tremors, chronic
pain due to failed back surgeries and other related neurological
disorders that may improve patient outcomes and reduce procedural
costs. The Company may also pursue applications for other areas
such as depression, mood disorders, pain, incontinence, high blood
pressure, and artificial intelligence. For more information,
visit www.nmtc1.com.
Forward Looking Statements
This press release may include forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Except for statements of historical fact, any
information contained in this press release may be a
forward–looking statement that reflects NeuroOne’s current views
about future events and are subject to known and unknown risks,
uncertainties and other factors that may cause our actual results,
levels of activity, performance or achievements to be materially
different from the information expressed or implied by these
forward-looking statements. In some cases, you can identify
forward–looking statements by the words or phrases "may," "might,"
"will," "could," "would," "should," "expect," "intend," "plan,"
"objective," "anticipate," "believe," "estimate," "predict,"
"project," "potential," "target," "seek," "contemplate," "continue,
"focused on," "committed to" and "ongoing," or the negative of
these terms, or other comparable terminology intended to identify
statements about the future. Forward–looking statements may include
statements regarding the ability of the OneRF Ablation System to
reduce hospital stays, reduce the number of surgeries, or reduce
adverse events. Although NeuroOne believes that we have a
reasonable basis for each forward-looking statement, we caution you
that these statements are based on a combination of facts and
factors currently known by us and our expectations of the future,
about which we cannot be certain. Our actual future results may be
materially different from what we expect due to factors largely
outside our control, including risks that our partnerships may not
facilitate the commercialization or market acceptance of our
technology; whether due to supply chain disruptions, labor
shortages, risks that our technology will not perform as expected
based on results of our pre-clinical and clinical trials; risks
related to uncertainties associated with the Company's capital
requirements to achieve its business objectives and ability to
raise additional funds; the risk that we may not be able to secure
or retain coverage or adequate reimbursement for our technology;
uncertainties inherent in the development process of our
technology; risks related to changes in regulatory requirements or
decisions of regulatory authorities; that we may not have
accurately estimated the size and growth potential of the markets
for our technology; risks related to our ability to protect our
intellectual property rights; and other risks, uncertainties and
assumptions, including those described under the heading "Risk
Factors" in our filings with the Securities and Exchange
Commission. These forward–looking statements speak only as of the
date of this press release and NeuroOne undertakes no obligation to
revise or update any forward–looking statements for any reason,
even if new information becomes available in the future.
“Caution: Federal law restricts this device to sale by or on the
order of a physician.
Contact:
800-631-4030 ir@nmtc1.com
NeuroOne Medical Technol... (NASDAQ:NMTC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
NeuroOne Medical Technol... (NASDAQ:NMTC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024